AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Medistim

Earnings Release • Oct 28, 2022

3662_rns_2022-10-28_41f18e63-16d7-4bff-8b80-692a6510d92d.html

Earnings Release

Open in Viewer

Opens in native device viewer

Third quarter results 2022 for Medistim ASA

Another strong quarter ending at MNOK 116.5 in sales (MNOK 102.1), up 14 %. YTD revenue ended at MNOK 350.1 (MNOK 314.5), up 11.3 %. Sales growth is driven by the USA with a currency neutral sales increase of 18.7 % for the quarter and 24.1 % YTD. The Vascular business segment grows at 26.7 % for the quarter and 36.0 % YTD. The imaging products grows at 44.1 % for the quarter and 47.9 %. YTD Currency neutral sales of own products increase 14.7 % for the quarter and 11.8 % YTD. Operating profit (EBIT) for the quarter ended at MNOK 34.0 (MNOK 25.1), an EBIT margin of 29.3% (24.6%). Operating profit YTD ended at MNOK 104.8 (MNOK 96.8), an EBIT margin of 29.9% (30.8%). New Guidelines from the European Society of Vascular Surgery (ESVS) recommending intraoperative ultrasound after Carotid Endareterectomy (CEA.